ATE533056T1 - Verfahren zum auffinden von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren - Google Patents

Verfahren zum auffinden von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren

Info

Publication number
ATE533056T1
ATE533056T1 AT04027975T AT04027975T ATE533056T1 AT E533056 T1 ATE533056 T1 AT E533056T1 AT 04027975 T AT04027975 T AT 04027975T AT 04027975 T AT04027975 T AT 04027975T AT E533056 T1 ATE533056 T1 AT E533056T1
Authority
AT
Austria
Prior art keywords
vegf
cells
tumor
screening
methods
Prior art date
Application number
AT04027975T
Other languages
English (en)
Inventor
Marc Achen
Steven Stacker
Original Assignee
Vegenics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vegenics Pty Ltd filed Critical Vegenics Pty Ltd
Application granted granted Critical
Publication of ATE533056T1 publication Critical patent/ATE533056T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04027975T 2000-03-02 2001-03-02 Verfahren zum auffinden von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren ATE533056T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18636100P 2000-03-02 2000-03-02

Publications (1)

Publication Number Publication Date
ATE533056T1 true ATE533056T1 (de) 2011-11-15

Family

ID=22684635

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04027975T ATE533056T1 (de) 2000-03-02 2001-03-02 Verfahren zum auffinden von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren
AT01913267T ATE284701T1 (de) 2000-03-02 2001-03-02 Methode zur behandlung von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01913267T ATE284701T1 (de) 2000-03-02 2001-03-02 Methode zur behandlung von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren

Country Status (12)

Country Link
US (1) US20010038842A1 (de)
EP (1) EP1259248B1 (de)
JP (1) JP2003525248A (de)
KR (1) KR20020080461A (de)
AT (2) ATE533056T1 (de)
AU (1) AU4194601A (de)
CA (1) CA2401665A1 (de)
DE (1) DE60107815T2 (de)
ES (2) ES2234818T3 (de)
NZ (1) NZ520546A (de)
PT (1) PT1259248E (de)
WO (1) WO2001064235A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
EP1353952B1 (de) * 1994-11-14 2007-04-11 Ludwig Institute For Cancer Research Flt4 (vegfr-3) als ein ziel für krebs darstellung und anti-krebs-behandlung
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2000041698A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
EP1425580A4 (de) * 2001-07-12 2006-03-29 Ludwig Inst Cancer Res Materialien und verfahren mit lymphatischen endothelzellen
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
EP2324825A1 (de) 2002-02-11 2011-05-25 Bayer Healthcare LLC Arylharnstoffe mit Angiogenese hemmender Aktivität
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US20050100963A1 (en) * 2002-03-01 2005-05-12 Dyax Corporation KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7261876B2 (en) * 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7666979B2 (en) * 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7985402B2 (en) * 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
JP2006517586A (ja) * 2003-02-04 2006-07-27 ラドウィグ インスティテュート フォー キャンサー リサーチ 幹細胞のｖｅｇｆ−ｂ及びｐｄｇｆ調節
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
ES2692166T3 (es) 2003-03-03 2018-11-30 Dyax Corp. Péptidos que se unen específicamente al receptor de HGF (cMet) y usos de los mismos
RU2248183C2 (ru) * 2003-03-11 2005-03-20 НИИ онкологии им. проф. Н.Н. Петрова Минздрава РФ Способ интраоперационной диагностики степени распространенности опухолевого процесса при колоректальном раке
DK1626714T3 (da) 2003-05-20 2007-10-15 Bayer Pharmaceuticals Corp Dirarylurinstoffer mod sygdomme medieret af PDGFR
US20050032697A1 (en) * 2003-06-12 2005-02-10 Kari Alitalo Heparin binding VEGFR-3 ligands
WO2005011722A2 (en) * 2003-06-12 2005-02-10 Ludwig Institute For Cancer Research Use of vegf-c or vegf-d in reconstructive surgery
CN1856469B (zh) 2003-07-23 2013-03-06 拜耳医药保健有限责任公司 用于治疗和预防疾病和疾病症状的氟代ω-羧芳基二苯基脲
WO2005037999A2 (en) * 2003-10-14 2005-04-28 Biogen Idec Ma Inc. Treatment of cancer using antibodies to lrrc15
DE102007037008B4 (de) * 2007-08-06 2015-09-10 Siemens Aktiengesellschaft Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors
US9981018B2 (en) 2010-06-08 2018-05-29 The Cleveland Clinic Foundation Compositions and methods for modulating toll-like receptor 2 activation
WO2011156451A2 (en) * 2010-06-08 2011-12-15 The Cleveland Clinic Foundation Compositions and methods for modulating toll-like receptor 2 activation
MX368730B (es) 2013-02-18 2019-10-14 Vegenics Pty Ltd Moleculas que unen ligando y usos de las mismas.
CN103739710B (zh) * 2014-01-26 2015-12-09 中国人民解放军军事医学科学院基础医学研究所 一种抗vegf抗体及其应用
JP2019533024A (ja) * 2016-11-16 2019-11-14 イーライ リリー アンド カンパニー 抗ｖｅｇｆｒ−２および抗ｖｅｇｆ−ｄ抗体を使用する転移性結腸直腸癌の治療

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE294863T1 (de) * 1996-07-15 2005-05-15 Chugai Pharmaceutical Co Ltd Neuartige vegf-ähnliche faktoren
AU729880C (en) * 1996-08-23 2001-11-08 Vegenics Limited Recombinant vascular endothelial cell growth factor D (VEGF-D)
CA2315977A1 (en) * 1997-12-24 1999-07-08 Ludwig Institute For Cancer Research Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas
WO2000037025A2 (en) * 1998-12-21 2000-06-29 Ludwig Institute For Cancer Research Antibodies to truncated vegf-d and uses thereof
HK1041500A1 (zh) * 1999-06-11 2002-07-12 Aventis Pharmaceuticals Products Inc. 通过丝氨酸/苏氨酸蛋白激酶akt诱导血管内皮生长因子(vegf)

Also Published As

Publication number Publication date
JP2003525248A (ja) 2003-08-26
DE60107815T2 (de) 2005-12-08
ATE284701T1 (de) 2005-01-15
CA2401665A1 (en) 2001-09-07
WO2001064235A1 (en) 2001-09-07
ES2377119T3 (es) 2012-03-22
ES2234818T3 (es) 2005-07-01
EP1259248B1 (de) 2004-12-15
EP1259248A4 (de) 2003-05-28
AU4194601A (en) 2001-09-12
PT1259248E (pt) 2005-04-29
DE60107815D1 (de) 2005-01-20
KR20020080461A (ko) 2002-10-23
NZ520546A (en) 2004-05-28
EP1259248A1 (de) 2002-11-27
US20010038842A1 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
ATE533056T1 (de) Verfahren zum auffinden von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren
Lowy et al. Tenascin C in metastasis: A view from the invasive front
Bigatto et al. TNF-α promotes invasive growth through the MET signaling pathway
Comerota et al. A histological and functional description of the tissue causing chronic postthrombotic venous obstruction
ATE529535T1 (de) Genexpressionsprofilierung in einer biopsie unterzogenem tumorgewebe
WO2005065418A3 (en) Compositions and methods of use of targeting peptides for diagnosis and therapy
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
ATE353974T1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
UA90082C2 (ru) Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25
ATE419516T1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
WO2000055629A3 (en) Methods of diagnosing and treating breast cancer
Akinpelu et al. The impact of tumor microenvironment: unraveling the role of physical cues in breast cancer progression
Reis-Filho et al. Maspin expression in normal skin and usual cutaneous carcinomas
DE60309887D1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
DE60044119D1 (de) Reagentien und verfahren zur erkennung von erkrankungen der brust
van Laarhoven et al. Effects of nicotinamide and carbogen in different murine colon carcinomas: immunohistochemical analysis of vascular architecture and microenvironmental parameters
Boueuf et al. Inhibition of adhesion breast cancer cells by anticoagulant drugs and cimetidine
ATE426813T1 (de) Verfahren zur dosierung von ngf zur in vitro diagnose von brustkrebs und therapeutische verwendung
Tien et al. Pancreatic carcinoma cells stimulate proliferation and matrix synthesis of hepatic stellate cells
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
WO2001055450A3 (en) AMPLIFIED GENES AT 17q23
Hsiao et al. Toll‐like receptor‐4 agonist inhibits motility and invasion of hepatoblastoma HepG2 cells in vitro
Arjama Establishment of patient-derived cancer models from melanoma for functional drug sensitivity and resistance testing
JP7082804B2 (ja) Ｒａｇｅアプタマーを含む癌を治療するための医薬組成物
Wronski et al. 1273 Crispr/cas9 mediated knockout of ripk4 impairs spheroid formation and wnt/β-catenin signaling in melanoma cells